Drugs / SOR102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06080048 | Oct 2023 → Oct 2024 | ulcerative colitis | Sorriso Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOR102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06080048 ↗ |
| Action | Inhibit | “bispecific inhibitor of TNF” PMID 41242336 ↗ Nov 2025 |
| Route | Oral | “SOR102 oral capsules” NCT06080048 ↗ |
| Target | TNF | “targeting TNF” PMID 41242336 ↗ Nov 2025 |